Search

Your search keyword '"Banzi M"' showing total 148 results
Start Over Author "Banzi M" Search Limiters Academic (Peer-Reviewed) Journals
148 results on '"Banzi M"'

1. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial

Author

Grassi, E., Zingaretti, C., Petracci, E., Corbelli, J., Papiani, G., Banchelli, I., Valli, I., Frassineti, G.L., Passardi, A., Di Bartolomeo, M., Pietrantonio, F., Gelsomino, F., Carandina, I., Banzi, M., Martella, L., Bonetti, A.V., Boccaccino, A., Molinari, C., Marisi, G., Ugolini, G., Nanni, O., and Tamberi, S.

Published
2023
Full Text
View/download PDF

3. Prognostic value of Body Mass Index in stage II/III colon cancer: post-hoc analysis from the TOSCA trial

Author

Basile, D., primary, Rosati, G., additional, Bergamo, F., additional, Garattini, S.K., additional, Banzi, M., additional, Zampino, M., additional, Bozzarelli, S., additional, Marchetti, P., additional, Galli, F., additional, Longarini, R., additional, Zaniboni, A., additional, Ferrari, D., additional, De Placido, S., additional, Frassineti, L., additional, Nicolini, M., additional, Cinieri, S., additional, Priscindiaro, M., additional, Ziranu, P., additional, Caccialanza, R., additional, Pastorino, A., additional, Mosconi, S., additional, and Aprile, G., additional

Published
2023
Full Text
View/download PDF

4. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

Author

Rosati, G, Lonardi, S, Galli, F, Di Bartolomeo, M, Ronzoni, M, Zampino, M, Banzi, M, Zaniboni, A, Pasini, F, Bozzarelli, S, Garattini, S, Ferrari, D, Montesarchio, V, Mambrini, A, Ciuffreda, L, Pusceddu, V, Carlomagno, C, Bidoli, P, Amoroso, D, Bochicchio, A, Frassineti, L, Corsi, D, Bilancia, D, Pastorino, A, De Stefano, A, Labianca, R, Iaffaioli, R, Nasti, G, Daniele, B, Zagonel, V, Pella, N, Aprile, G, Marchetti, R, Romiti, A, Foa, P, Mosconi, S, Sobrero, A, Cazzaniga, M, Beretta, G, Cortesi, E, Barni, S, Petrelli, F, Allione, P, D'Arco, A, Valmadre, G, Piazza, E, Veltri, E, Ramus, G, Giustini, L, Tumulo, S, Cascinu, S, Granetto, C, Testore, F, Giordano, M, Moroni, M, Di Seri, M, Nuzzo, A, Angelelli, L, Gori, S, Farina, G, Aglietta, M, Franchi, R, Comande, M, Giordani, P, Tonini, G, Bucci, E, Ballestrero, A, Benasso, M, Graiff, C, Bravi, S, Caffo, O, Silva, R, Frontini, L, Rota, S, Cozzi, L, Cantore, M, Maiello, E, Cinieri, S, Silvestris, N, Romito, S, Gebbia, V, Santoro, A, Artioli, F, Mattioli, R, Contu, A, Di Costanzo, F, Leonardi, F, Cavanna, L, Passalacqua, R, Sozzi, P, D'Amico, M, Amadori, D, Turci, D, Ravaioli, A, Pasquini, E, Gambi, A, Faedi, M, Cruciani, G, Bajetta, E, Gianni, L, Ionta, M, Massidda, B, Scartozzi, M, Ciarlo, A, Di Leo, A, Frustaci, S, Rangoni, G, Arizzoia, A, Pavesi, L, Verusio, C, Pinotti, G, Iop, A, De Placido, S, Adamo, V, Ficorella, C, Natale, D, Greco, E, Rulli, E, Poli, D, Porcu, L, Torri, V, Rosati G., Lonardi S., Galli F., Di Bartolomeo M., Ronzoni M., Zampino M. G., Banzi M., Zaniboni A., Pasini F., Bozzarelli S., Garattini S. K., Ferrari D., Montesarchio V., Mambrini A., Ciuffreda L., Pusceddu V., Carlomagno C., Bidoli P., Amoroso D., Bochicchio A. M., Frassineti L., Corsi D., Bilancia D., Pastorino A., De Stefano A., Labianca R., Iaffaioli R. V., Nasti G., Daniele B., Zagonel V., Pella N., Aprile G., Marchetti R. P., Romiti A., Foa P., Mosconi S., Sobrero A., Cazzaniga M., Beretta G. D., Cortesi E., Barni S., Petrelli F., Allione P., D'Arco A. M., Valmadre G., Piazza E., Veltri E., Ramus G. V., Giustini L., Tumulo S., Cascinu S., Granetto C., Testore F., Giordano M., Moroni M., Di Seri M., Nuzzo A., Angelelli L., Gori S., Farina G., Aglietta M., Franchi R., Comande M., Giordani P., Tonini G., Bucci E., Ballestrero A., Benasso M., Graiff C., Bravi S., Caffo O., Silva R. R., Frontini L., Rota S., Cozzi L., Cantore M., Maiello E., Cinieri S., Silvestris N., Romito S., Gebbia V., Santoro A., Artioli F., Mattioli R., Contu A., Di Costanzo F., Leonardi F., Cavanna L., Passalacqua R., Sozzi P., D'Amico M., Amadori D., Turci D., Ravaioli A., Pasquini E., Gambi A., Faedi M., Cruciani G., Bajetta E., Gianni L., Ionta M. T., Massidda B., Scartozzi M., Ciarlo A., Di Leo A., Frustaci S., Rangoni G., Arizzoia A., Pavesi L., Verusio C., Pinotti G., Iop A., De Placido S., Adamo V., Ficorella C., Natale D., Greco E., Rulli E., Poli D., Porcu L., Torri V., Rosati, G, Lonardi, S, Galli, F, Di Bartolomeo, M, Ronzoni, M, Zampino, M, Banzi, M, Zaniboni, A, Pasini, F, Bozzarelli, S, Garattini, S, Ferrari, D, Montesarchio, V, Mambrini, A, Ciuffreda, L, Pusceddu, V, Carlomagno, C, Bidoli, P, Amoroso, D, Bochicchio, A, Frassineti, L, Corsi, D, Bilancia, D, Pastorino, A, De Stefano, A, Labianca, R, Iaffaioli, R, Nasti, G, Daniele, B, Zagonel, V, Pella, N, Aprile, G, Marchetti, R, Romiti, A, Foa, P, Mosconi, S, Sobrero, A, Cazzaniga, M, Beretta, G, Cortesi, E, Barni, S, Petrelli, F, Allione, P, D'Arco, A, Valmadre, G, Piazza, E, Veltri, E, Ramus, G, Giustini, L, Tumulo, S, Cascinu, S, Granetto, C, Testore, F, Giordano, M, Moroni, M, Di Seri, M, Nuzzo, A, Angelelli, L, Gori, S, Farina, G, Aglietta, M, Franchi, R, Comande, M, Giordani, P, Tonini, G, Bucci, E, Ballestrero, A, Benasso, M, Graiff, C, Bravi, S, Caffo, O, Silva, R, Frontini, L, Rota, S, Cozzi, L, Cantore, M, Maiello, E, Cinieri, S, Silvestris, N, Romito, S, Gebbia, V, Santoro, A, Artioli, F, Mattioli, R, Contu, A, Di Costanzo, F, Leonardi, F, Cavanna, L, Passalacqua, R, Sozzi, P, D'Amico, M, Amadori, D, Turci, D, Ravaioli, A, Pasquini, E, Gambi, A, Faedi, M, Cruciani, G, Bajetta, E, Gianni, L, Ionta, M, Massidda, B, Scartozzi, M, Ciarlo, A, Di Leo, A, Frustaci, S, Rangoni, G, Arizzoia, A, Pavesi, L, Verusio, C, Pinotti, G, Iop, A, De Placido, S, Adamo, V, Ficorella, C, Natale, D, Greco, E, Rulli, E, Poli, D, Porcu, L, Torri, V, Rosati G., Lonardi S., Galli F., Di Bartolomeo M., Ronzoni M., Zampino M. G., Banzi M., Zaniboni A., Pasini F., Bozzarelli S., Garattini S. K., Ferrari D., Montesarchio V., Mambrini A., Ciuffreda L., Pusceddu V., Carlomagno C., Bidoli P., Amoroso D., Bochicchio A. M., Frassineti L., Corsi D., Bilancia D., Pastorino A., De Stefano A., Labianca R., Iaffaioli R. V., Nasti G., Daniele B., Zagonel V., Pella N., Aprile G., Marchetti R. P., Romiti A., Foa P., Mosconi S., Sobrero A., Cazzaniga M., Beretta G. D., Cortesi E., Barni S., Petrelli F., Allione P., D'Arco A. M., Valmadre G., Piazza E., Veltri E., Ramus G. V., Giustini L., Tumulo S., Cascinu S., Granetto C., Testore F., Giordano M., Moroni M., Di Seri M., Nuzzo A., Angelelli L., Gori S., Farina G., Aglietta M., Franchi R., Comande M., Giordani P., Tonini G., Bucci E., Ballestrero A., Benasso M., Graiff C., Bravi S., Caffo O., Silva R. R., Frontini L., Rota S., Cozzi L., Cantore M., Maiello E., Cinieri S., Silvestris N., Romito S., Gebbia V., Santoro A., Artioli F., Mattioli R., Contu A., Di Costanzo F., Leonardi F., Cavanna L., Passalacqua R., Sozzi P., D'Amico M., Amadori D., Turci D., Ravaioli A., Pasquini E., Gambi A., Faedi M., Cruciani G., Bajetta E., Gianni L., Ionta M. T., Massidda B., Scartozzi M., Ciarlo A., Di Leo A., Frustaci S., Rangoni G., Arizzoia A., Pavesi L., Verusio C., Pinotti G., Iop A., De Placido S., Adamo V., Ficorella C., Natale D., Greco E., Rulli E., Poli D., Porcu L., and Torri V.

Abstract

Background: Previous studies on oxaliplatin and fluoropyrimidines as adjuvant therapy in older patients with stage III colon cancer (CC) produced conflicting results. Patients and methods: We assessed the impact of age on time to tumour recurrence (TTR), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) in 2360 patients with stage III CC (1667 aged <70 years and 693 ≥ 70 years) randomised to receive 3 or 6 months of FOLFOX or CAPOX within the frame of the phase III, TOSCA study. Results: Older patients compared with younger ones presented more frequently an Eastern Cooperative Oncology Group performance status equal to 1 (10.5% vs 3.3%, p < 0.001), a greater number of right-sided tumours (40.9% vs 26.6%, p < 0.001), and were at higher clinical risk (37.2% vs 33.2%, p = 0.062). The treatments were almost identical in the two cohorts (p = 0.965). We found a greater proportion of dose reductions (46.7% vs 41.4%, p = 0.018), treatment interruptions (26.1% vs 19.3%, p < 0.001) and a higher proportion of recurrences (24.2% vs 20.3%, p = 0.033) in the older patients. The multivariable analysis of the TTR did not indicate a statistically significant effect of age (hazard ratio [HR]: 1.19; 95% confidence interval [CI]: 0.98–1.44; p = 0.082). The HR comparing older with younger patients was 1.34 (95% CI: 1.12–1.59; p = 0.001) for DFS, 1.58 (95% CI: 1.26–1.99; p < 0.001) for OS, and 1.28 (95% CI: 0.96–1.70; p = 0.089) for CSS. Conclusions: Worse prognostic factors and reduced treatment compliance have a negative impact on the efficacy of oxaliplatin-based adjuvant therapy in older patients.

Published
2021

6. Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial

Author

Barni, S, Rosati, G, Lonardi, S, Pella, N, Banzi, M, Zampino, M, Dotti, K, Rimassa, L, Marchetti, P, Maiello, E, Artioli, F, Ferrari, D, Labianca, R, Bidoli, P, Zaniboni, A, Sobrero, A, Iaffaioli, V, De Placido, S, Frassineti, G, Ciarlo, A, Buonadonna, A, Silvestris, N, Piazza, E, Pavesi, L, Moroni, M, Clerico, M, Aglietta, M, Giordani, P, Galli, F, Petrelli, F, Barni S., Rosati G., Lonardi S., Pella N., Banzi M., Zampino M. G., Dotti K. F., Rimassa L., Marchetti P., Maiello E., Artioli F., Ferrari D., Labianca R., Bidoli P., Zaniboni A., Sobrero A., Iaffaioli V., De Placido S., Frassineti G. L., Ciarlo A., Buonadonna A., Silvestris N., Piazza E., Pavesi L., Moroni M., Clerico M., Aglietta M., Giordani P., Galli F., Petrelli F., Barni, S, Rosati, G, Lonardi, S, Pella, N, Banzi, M, Zampino, M, Dotti, K, Rimassa, L, Marchetti, P, Maiello, E, Artioli, F, Ferrari, D, Labianca, R, Bidoli, P, Zaniboni, A, Sobrero, A, Iaffaioli, V, De Placido, S, Frassineti, G, Ciarlo, A, Buonadonna, A, Silvestris, N, Piazza, E, Pavesi, L, Moroni, M, Clerico, M, Aglietta, M, Giordani, P, Galli, F, Petrelli, F, Barni S., Rosati G., Lonardi S., Pella N., Banzi M., Zampino M. G., Dotti K. F., Rimassa L., Marchetti P., Maiello E., Artioli F., Ferrari D., Labianca R., Bidoli P., Zaniboni A., Sobrero A., Iaffaioli V., De Placido S., Frassineti G. L., Ciarlo A., Buonadonna A., Silvestris N., Piazza E., Pavesi L., Moroni M., Clerico M., Aglietta M., Giordani P., Galli F., and Petrelli F.

Abstract

Background: The risk of venous thromboembolic events (VTE) during adjuvant chemotherapy for colorectal cancer (CRC) is unknown. We aim to evaluate if the Khorana score (KS) can predict this risk, and if it represents a prognostic factor for overall survival (OS) through a post hoc analysis of the phase III TOSCA trial of different durations (3- versus 6-months) of adjuvant chemotherapy. Methods: A logistic regression model was used to test the associations between the risk of VTE and the KS. The results are expressed as odds ratios (OR) with 95% confidence intervals (95% CI). To assess the effect of the KS on OS, multivariable analyses using Cox regression models were performed. The results are expressed as hazard ratios (HR) with 95% CI. Results: Among 1380 CRC patients with available data, the VTE risk (n = 72 events: 5.2%) was similar in the two duration arms (5.5% versus 4.9%), with 0.2% of patients belonging to the high-risk KS group. Rates of VTE were similar in the low- and intermediate-risk groups (4.8% versus 6.4%). KS did not represent an independent predictive factor for VTE occurrence. Chemotherapy duration was not associated with VTE risk. In addition, KS was not prognostic for OS in multivariate analysis (HR: 0.92, 95% CI, 0.63–1.36; p = 0.6835). Conclusions: The use of the KS did not predict VTEs in a low–moderate thromboembolic risk population as CRC. These data did not support the use of KS to predict VTE during adjuvant chemotherapy, and suggest that other risk assessment models should be researched.

Published
2020

8. O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO

Author

Antoniotti, C., Cremolini, C., Loupakis, F., Bergamo, F., Grande, R., Tonini, G., Garattini Silvio, K., Masi, G., Battaglin, F., Lucchesi, S., Salvatore, L., Corsi, D., Di Fabio, F., Banzi, M., Moretto, R., Sensi, E., Rossini, D., Tomcikova, D., Fontanini, G., Zagonel, V., Boni, L., and Falcone, A.

Published
2016
Full Text
View/download PDF

9. 2248P Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results

Author

Tamberi, S., Marisi, G., Molinari, C., Grassi, E., Petracci, E., Angeli, D., Virga, A., Banchelli, I., Zingaretti, C., Pietrantonio, F., Gelsomino, F., Carandina, I., Banzi, M., Bonetti, A., Frassineti, G.L., Ugolini, G., Santucci, S., Longobardi, J., and Ulivi, P.

Published
2023
Full Text
View/download PDF

10. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial

Author

Rosati, Gerardo, primary, Lonardi, Sara, additional, Galli, Fabio, additional, Di Bartolomeo, Maria, additional, Ronzoni, Monica, additional, Zampino, Maria G., additional, Banzi, Maria, additional, Zaniboni, Alberto, additional, Pasini, Felice, additional, Bozzarelli, Silvia, additional, Garattini, Silvio K., additional, Ferrari, Daris, additional, Montesarchio, Vincenzo, additional, Mambrini, Andrea, additional, Ciuffreda, Libero, additional, Galli, Francesca, additional, Pusceddu, Valeria, additional, Carlomagno, Chiara, additional, Bidoli, Paolo, additional, Amoroso, Domenico, additional, Bochicchio, Anna M., additional, Frassineti, Luca, additional, Corsi, Domenico, additional, Bilancia, Domenico, additional, Pastorino, Alessandro, additional, De Stefano, Alfonso, additional, Labianca, Roberto, additional, Bilancia, D., additional, Rosati, G., additional, Montesarchio, V., additional, Iaffaioli, R.V., additional, Nasti, G., additional, Daniele, B., additional, Zagonel, V., additional, Lonardi, S., additional, Pella, N., additional, Aprile, G., additional, Pasini, F., additional, Marchetti, Roma P., additional, Romiti, A., additional, Ciuffreda, L., additional, Ferrari, D., additional, Foa, P., additional, Zaniboni, A., additional, Labianca, R., additional, Mosconi, S., additional, Sobrero, A., additional, Bidoli, P., additional, Cazzaniga, M., additional, Beretta, G.D., additional, Corsi, D.C., additional, Cortesi, E., additional, Barni, S., additional, Petrelli, F., additional, Allione, P., additional, D'Arco, A.M., additional, Valmadre, G., additional, Piazza, E., additional, Veltri, E., additional, Ramus, G. Vietti, additional, Giustini, L., additional, Tumulo, S., additional, Cascinu, S., additional, Granetto, C., additional, Testore, F., additional, Giordano, M., additional, Moroni, M., additional, Di Seri, M., additional, Nuzzo, A., additional, Angelelli, L., additional, Gori, S., additional, Farina, G., additional, Aglietta, M., additional, Franchi, R., additional, Comandé, M., additional, Giordani, P., additional, Tonini, G., additional, Bucci, E., additional, Ballestrero, A., additional, Benasso, M., additional, Graiff, C., additional, Bravi, S., additional, Caffo, O., additional, Silva, R.R., additional, Frontini, L., additional, Rota, S., additional, Cozzi, L., additional, Cantore, M., additional, Maiello, E., additional, Cinieri, S., additional, Silvestris, N., additional, Romito, S., additional, Gebbia, V., additional, Banzi, M., additional, Santoro, A., additional, Artioli, F., additional, Mattioli, R., additional, Contu, A., additional, Di Costanzo, F., additional, Leonardi, F., additional, Cavanna, L., additional, Passalacqua, R., additional, Amoroso, D., additional, Sozzi, P., additional, D'Amico, M., additional, Amadori, D., additional, Frassineti, L., additional, Turci, D., additional, Ravaioli, A., additional, Pasquini, E., additional, Gambi, A., additional, Faedi, M., additional, Cruciani, G., additional, Bajetta, E., additional, Di Bartolomeo, M., additional, Gianni, L., additional, Ronzoni, M., additional, Ionta, M.T., additional, Massidda, B., additional, Scartozzi, M., additional, Zampino, M.G., additional, Bochicchio, A.M., additional, Ciarlo, A., additional, Di Leo, A., additional, Frustaci, S., additional, Rangoni, G., additional, Arizzoia, A., additional, Pavesi, L., additional, Verusio, C., additional, Pinotti, G., additional, Iop, A., additional, De Placido, S., additional, Carlomagno, C., additional, Adamo, V., additional, Ficorella, C., additional, Natale, D., additional, Greco, E., additional, Rulli, E., additional, Galli, F., additional, Poli, D., additional, Porcu, L., additional, and Torri, V., additional

Published
2021
Full Text
View/download PDF

11. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis

Author

Pressiani, T., Boni, C., Rimassa, L., Labianca, R., Fagiuoli, S., Salvagni, S., Ferrari, D., Cortesi, E., Porta, C., Mucciarini, C., Latini, L., Carnaghi, C., Banzi, M., Fanello, S., De Giorgio, M., Lutman, F. R., Torzilli, G., Tommasini, M. A., Ceriani, R., Covini, G., Tronconi, M. C., Giordano, L., Locopo, N., Naimo, S., and Santoro, A.

Published
2013
Full Text
View/download PDF

12. 447P Long term survival with regorafenib: REALITY (real life in Italy) trial - A GISCAD Study

Author

Lai, E., primary, Cremolini, C., additional, Puzzoni, M., additional, Bergamo, F., additional, Zucchelli, G., additional, Libertini, M., additional, Dettori, M., additional, Banzi, M., additional, Boccaccino, A., additional, Cinieri, S., additional, Cavo, A., additional, Piacentini, G., additional, Andreozzi, F., additional, Banna, G.L., additional, Nappo, F., additional, Iachetta, F., additional, Rota, S., additional, Conca, V., additional, Zaniboni, A., additional, and Scartozzi, M., additional

Published
2020
Full Text
View/download PDF

13. 399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial

Author

Rosati, G., primary, Galli, F., additional, Lonardi, S., additional, Dotti, K.F., additional, Ronzoni, M., additional, Zampino, M.G., additional, Banzi, M., additional, Pusceddu, V., additional, Pasini, F., additional, Bozzarelli, S., additional, Pella, N., additional, Codecà, C., additional, Montesarchio, V., additional, Mambrini, A., additional, De Stefano, A., additional, Ciuffreda, L., additional, Rebuzzi, S.E., additional, Bilancia, D., additional, and Labianca, R., additional

Published
2020
Full Text
View/download PDF

14. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

Author

Vernieri, C, Galli, F, Ferrari, L, Marchetti, P, Lonardi, S, Maiello, E, Iaffaioli, R, Zampino, M, Zaniboni, A, De Placido, S, Banzi, M, Damiani, A, Ferrari, D, Rosati, G, Labianca, R, Bidoli, P, Frassineti, G, Nicolini, M, Pavesi, L, Tronconi, M, Buonadonna, A, Ferrario, S, Re, G, Adamo, V, Tamburini, E, Clerico, M, Giordani, P, Leonardi, F, Barni, S, Ciarlo, A, Cavanna, L, Gori, S, Cinieri, S, Faedi, M, Aglietta, M, Antista, M, Dotti, K, Di Bartolomeo, M, Iaffaioli, RV, Zampino, MG, Labianca, RF, Frassineti, GL, Tronconi, MC, Re, GL, Dotti, KF, Vernieri, C, Galli, F, Ferrari, L, Marchetti, P, Lonardi, S, Maiello, E, Iaffaioli, R, Zampino, M, Zaniboni, A, De Placido, S, Banzi, M, Damiani, A, Ferrari, D, Rosati, G, Labianca, R, Bidoli, P, Frassineti, G, Nicolini, M, Pavesi, L, Tronconi, M, Buonadonna, A, Ferrario, S, Re, G, Adamo, V, Tamburini, E, Clerico, M, Giordani, P, Leonardi, F, Barni, S, Ciarlo, A, Cavanna, L, Gori, S, Cinieri, S, Faedi, M, Aglietta, M, Antista, M, Dotti, K, Di Bartolomeo, M, Iaffaioli, RV, Zampino, MG, Labianca, RF, Frassineti, GL, Tronconi, MC, Re, GL, and Dotti, KF

Abstract

Background: Type 2 diabetes mellitus (T2DM) is associated with increased risk of colon cancer (CC), whereas metformin use seems to be protective. However, the impact of metformin use on the risk of death or disease recurrence after radical surgery for CC remains uncertain. Materials and Methods: This is a substudy conducted in patients with high-risk stage II or stage III CC randomized in the TOSCA trial, which compared 3 versus 6 months of fluoropyrimidine-oxaliplatin adjuvant chemotherapy. Objective of the study was to investigate the impact of metformin exposure during adjuvant chemotherapy on overall survival (OS) and relapse-free survival (RFS). We also evaluated the impact of T2DM or metformin dosage on clinical outcomes. Results: Out of 3,759 patients enrolled in the TOSCA trial, 133 patients with diabetes (9.2%) and 1,319 without diabetes (90.8%) were recruited in this study. After excluding 13 patients with diabetes without information on metformin exposure, 76 patients with T2DM (63.3%) were defined as metformin users and 44 (36.7%) as metformin nonusers. After a median follow-up of 60.4 months, 26 (21.7%) patients relapsed and 16 (13.3%) died. Metformin use was neither associated with OS (adjusted hazard ratio [HR], 1.51; 95% confidence interval [CI], 0.48–4.77; p =.4781) nor with RFS (HR, 1.56; 95% CI, 0.69–3.54; p =.2881). Similarly, we found no association between T2DM or metformin dosage and OS or RFS. Conclusions: Metformin use and T2DM did not impact on OS or RFS in patients with resected CC treated with adjuvant fluoropyrimidine-oxaliplatin chemotherapy. Larger studies and longer follow-up are required to clarify the potential efficacy of metformin in improving the prognosis of patients with CC. Implications for Practice: The role of the antidiabetic drug metformin in colon cancer prevention and treatment is highly debated. While low-dose metformin reduced the incidence of colorectal adenomas in two prospective studies, its effect in patients with

Published
2019

19. Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial

Author

Lonardi, S, Sobrero, A, Rosati, G, Di Bartolomeo, M, Ronzoni, M, Aprile, G, Scartozzi, M, Banzi, M, Zampino, M, Pasini, F, Marchetti, P, Cantore, M, Zaniboni, A, Rimassa, L, Ciuffreda, L, Ferrari, D, Barni, S, Zagonel, V, Maiello, E, Rulli, E, Labianca, R, Bidoli, P, Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R, Bidoli P, Lonardi, S, Sobrero, A, Rosati, G, Di Bartolomeo, M, Ronzoni, M, Aprile, G, Scartozzi, M, Banzi, M, Zampino, M, Pasini, F, Marchetti, P, Cantore, M, Zaniboni, A, Rimassa, L, Ciuffreda, L, Ferrari, D, Barni, S, Zagonel, V, Maiello, E, Rulli, E, Labianca, R, Bidoli, P, Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R, and Bidoli P

Abstract

Background: Six months of oxaliplatin-based adjuvant chemotherapy is standard of care for radically resected stage III colon cancer and an accepted option for high-risk stage II. A shorter duration of therapy, if equally efficacious, would be advantageous for patients and Health-Care Systems. Patients and methods: TOSCA ['Randomized trial investigating the role of FOLFOX-4 or XELOX (3 versus 6 months) regimen duration and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer] is an open-label, phase III, multicenter, noninferiority trial randomizing patients with high-risk stage II or stage III radically resected colon cancer to receive 3 months (arm 3 m) versus 6 months (arm 6 m) of FOLFOX4/XELOX. Primary end-point was relapse-free survival. We present here safety and compliance data. Results: From June 2007 to March 2013, 3759 patients were accrued from 130 Italian sites, 64% receiving FOLFOX4 and 36% XELOX in either arm. Treatment completion rate without any modification was 35% versus 12% and with delays or dose reduction 52% versus 44% in arm 3 and 6 m. Treatment was permanently discontinued in 8% (arm 3 m) and 33% (arm 6 m). In arm 6 m, 50% of patients discontinuing treatment did so after completing 80% of planned program. Grade 3+ toxicities were higher in arm 6 m than that in 3 m. Grade 2+ neuropathy was 31.2% versus 8.8% (P < 0.0001) while grade 3+ was 8.4 versus 1.3 (P < 0.0001), in arm 3 and 6 m. Seven deaths within 30 days from last treatment administration in arm 6 m and three deaths in arm 3 m were observed (0.3% versus 0.1%, P = 0.34). Conclusions: TOSCA is the first trial comparing 3 versus 6 months of adjuvant chemotherapy completing accrual within the international initiative of treatment duration evaluation (International Duration Evaluation of Adjuvant, IDEA). High compliance to treatment in control arm will allow a correct assessment of potential differences between the two treatment durations.

Published
2016

20. Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial

Author

Cascinu, S., primary, Berardi, R., additional, Bianco, R., additional, Bilancia, D., additional, Zaniboni, A., additional, Ferrari, D., additional, Mosconi, S., additional, Spallanzani, A., additional, Cavanna, L., additional, Leo, S., additional, Negri, F., additional, Beretta, G.D., additional, Sobrero, A., additional, Banzi, M., additional, Morabito, A., additional, Bittoni, A., additional, Marciano, R., additional, Ferrara, D., additional, Noventa, S., additional, and Piccirillo, M.C., additional

Published
2019
Full Text
View/download PDF

21. Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis

Author

Rosati, G., primary, Galli, F., additional, Cantore, M., additional, Lonardi, S., additional, Banzi, M., additional, Zampino, M.G., additional, Mattioli, R., additional, Pella, N., additional, Ronzoni, M., additional, Bartolomeo, M Di, additional, Tamberi, S., additional, Marchetti, P., additional, Bozzarelli, S., additional, Corsi, D.C., additional, Bochicchio, A.M., additional, Artioli, F., additional, Labianca, R., additional, Bilancia, D., additional, and Bregni, G., additional

Published
2019
Full Text
View/download PDF

22. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group

Author

De Gramont, A., primary, Henriques, J., additional, Baruch, B., additional, Kim, T.W., additional, Martinez-Villacampa, M., additional, Gallego-Plazas, J., additional, Cervantes, A., additional, Shim, K., additional, Jonker, D.J., additional, Guerin-Meyer, V., additional, Mineur, L., additional, Banzi, M., additional, Dewdney, A., additional, Dejthevaporn, T Sirisingha, additional, Bloemendal, H.J., additional, Roth, A.D., additional, Thompson, P., additional, Moehler, M., additional, Aguilar, E Aranda, additional, and André, T., additional

Published
2019
Full Text
View/download PDF

23. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials

Author

Cascinu, S., primary, Poli, D., additional, Zaniboni, A., additional, Lonardi, S., additional, Labianca, R., additional, Sobrero, A., additional, Rosati, G., additional, Di Bartolomeo, M., additional, Scartozzi, M., additional, Zagonel, V., additional, Pella, N., additional, Banzi, M., additional, and Torri, V., additional

Published
2019
Full Text
View/download PDF

24. Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial

Author

Barni, S., primary, Rosati, G., additional, Zagonel, V., additional, Pella, N., additional, Banzi, M., additional, Zampino, M.G., additional, Di Bartolomeo, M., additional, Rimassa, L., additional, Marchetti, P., additional, Maiello, E., additional, Artioli, F., additional, Ferrari, D., additional, Labianca, R., additional, Bidoli, P., additional, Zaniboni, A., additional, Sobrero, A., additional, Iaffaioli, V., additional, de Placido, S., additional, Frassineti, L.G., additional, Galli, F., additional, and Petrelli, F., additional

Published
2018
Full Text
View/download PDF

25. Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial

Author

Petrelli, F., primary, Rosati, G., additional, Banzi, M., additional, Zampino, M.G., additional, Pella, N., additional, Di Bartolomeo, M., additional, Maiello, E., additional, Bidoli, P., additional, Ferrari, D., additional, Rimassa, L., additional, Labianca, R., additional, Scartozzi, M., additional, Lonardi, S., additional, de Placido, S., additional, Zaniboni, A., additional, Sobrero, A., additional, Frassineti, L.G., additional, Silvestris, N., additional, Corsi, D., additional, Galli, F., additional, and Barni, S., additional

Published
2018
Full Text
View/download PDF

26. Correlation, in a real-world setting, between clinical-disease characteristics and compliance with immunotherapy in solid metastatic tumors: First results of an Italian CORE-IMMUNO study

Author

Masini, C., primary, Berselli, A., additional, Banzi, M., additional, Bonelli, C., additional, Romagnani, A., additional, Pagano, M., additional, Damato, A., additional, Prati, G., additional, Gasparini, E., additional, Moretti, G., additional, Lorenzetti, I.T., additional, Zanelli, F., additional, Iachetta, F., additional, and Pinto, C., additional

Published
2018
Full Text
View/download PDF

28. Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial

Author

Dell'Aquila, E., primary, Pantano, F., additional, Rossini, D., additional, Stellato, M., additional, Lonardi, S., additional, Masi, G., additional, Schirripa, M., additional, Marmorino, F., additional, Antoniotti, C., additional, Murgioni, S., additional, Tomasello, G., additional, Ronzoni, M., additional, Racca, P., additional, Vincenzi, B., additional, Allegrini, G., additional, Urbano, F., additional, Buonadonna, A., additional, Banzi, M., additional, Tonini, G., additional, Cremolini, C., additional, Falcone, A., additional, and Santini, D., additional

Published
2018
Full Text
View/download PDF

29. Correction to: Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial

Author

Lonardi, S., primary, Sobrero, A., additional, Rosati, G., additional, Di Bartolomeo, M., additional, Ronzoni, M., additional, Aprile, G., additional, Massida, B., additional, Scartozzi, M., additional, Banzi, M., additional, Zampino, M.G., additional, Pasini, F., additional, Marchetti, P., additional, Cantore, M., additional, Zaniboni, A., additional, Rimassa, L., additional, Ciuffreda, L., additional, Ferrari, D., additional, Barni, S., additional, Zagonel, V., additional, Maiello, E., additional, Rulli, E., additional, and Labianca, R., additional

Published
2017
Full Text
View/download PDF

30. A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Author

Rimassa, L, Pressiani, T, Boni, C, Carnaghi, C, Rota Caremoli, E, Fagiuoli, S, Foa, P, Salvagni, S, Cortesi, E, Chiara Tronconi, M, Personeni, N, Bozzarelli, S, Chiara Banzi, M, Fanello, S, Romano Lutman, F, Giordano, L, Santoro, A, Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S, Foa P, Salvagni S, Cortesi E, Chiara Tronconi M, Personeni N, Bozzarelli S, Chiara Banzi M, Fanello S, Romano Lutman F, Giordano L, Santoro A., Rimassa, L, Pressiani, T, Boni, C, Carnaghi, C, Rota Caremoli, E, Fagiuoli, S, Foa, P, Salvagni, S, Cortesi, E, Chiara Tronconi, M, Personeni, N, Bozzarelli, S, Chiara Banzi, M, Fanello, S, Romano Lutman, F, Giordano, L, Santoro, A, Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S, Foa P, Salvagni S, Cortesi E, Chiara Tronconi M, Personeni N, Bozzarelli S, Chiara Banzi M, Fanello S, Romano Lutman F, Giordano L, and Santoro A.

Abstract

Background. Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC). The viability of continuing sorafenib at a higher dosage in patients who experienced radiologic disease progression was investigated. Methods. Patients who experienced disease progression while on sorafenib 400 mg twice daily were randomized to sorafenib 600mgtwice daily (n49) or best supportive care (n52). The primary end point was progression-free survival (PFS). Time to progression, overall survival,andsafetywerealso evaluated. Results. The study did not meet its primary end point. The difference in PFS between the sorafenib arm (3.91 months) and the best supportive care arm (2.69 months) did not reach statistical significance (p = 0.086). Adverse events were mainly grade 1-2 and similar across both groups. In the sorafenib arm, the most frequent events were diarrhea (80%), weight loss (75%), fatigue (67%), hand-foot-skin reaction (49%), abdominal pain (37%), and stomatitis (26%). Conclusions. Escalated-dose sorafenib in patients with advanced HCC who progressed while on sorafenib, failed to provide any clinical benefit. Second-line treatment still remains an open issue to be explored in appropriate clinical trials

Published
2013

31. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.

Author

Pressiani, T, Boni, C, Rimassa, L, Labianca, R, Fagiuoli, S, Salvagni, S, Ferrari, D, Cortesi, E, Porta, C, Mucciarini, C, Latini, L, Carnaghi, C, Banzi, M, Fanello, S, De Giorgio, M, Lutman, F, Torzilli, G, Tommasini, M, Ceriani, R, Covini, G, Tronconi, M, Giordano, L, Locopo, N, Naimo, S, Santoro, A, Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A., Pressiani, T, Boni, C, Rimassa, L, Labianca, R, Fagiuoli, S, Salvagni, S, Ferrari, D, Cortesi, E, Porta, C, Mucciarini, C, Latini, L, Carnaghi, C, Banzi, M, Fanello, S, De Giorgio, M, Lutman, F, Torzilli, G, Tommasini, M, Ceriani, R, Covini, G, Tronconi, M, Giordano, L, Locopo, N, Naimo, S, Santoro, A, Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, and Santoro A.

Abstract

Background: Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function. There are few prospective data on sorafenib in patients with HCC and CP class B. Patients and methods: A consecutive prospective series of 300 patients with CP class A or B HCC were enrolled in a dual-phase trial to determine survival and safety data according to liver function (class A or B) in patients receiving oral sorafenib 800 mg daily. [Results of this study were presented in part at the ASCO 2012 Gastrointestinal Cancers Symposium, 19-21 January 2012. J Clin Oncol 2012; 30 (Suppl 4): abstract 306.]. Results: Overall progression-free survival (PFS), time to progression (TTP) and overall survival (OS) were 3.9, 4.1 and 9.1 months, respectively. For patients with CP class A versus B status, PFS was 4.3 versus 2.1 months, TTP was 4.2 versus 3.8 months and OS was 10.0 versus 3. 8 months. Extrahepatic spread was associated with worse outcomes but taken together with CP class, liver function played a greater role in reducing survival. Adverse events for the two CP groups were similar. Conclusion: Although patients with HCC and CP class B liver function have poorer outcomes than those with CP class A function, data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib.

Published
2013

32. FOLFOX4/XELOX in stage II–III colon cancer: early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial

Author

Zaniboni, A., primary, Lonardi, S., additional, Labianca, R., additional, Di Bartolomeo, M., additional, Rosati, G., additional, Ronzoni, M., additional, Pella, N., additional, Banzi, M., additional, Zampino, M.G., additional, Pasini, F., additional, Marchetti, P., additional, Rimassa, L., additional, Maiello, E., additional, Bidoli, P., additional, Cinieri, S., additional, Barni, S., additional, Ciuffreda, L., additional, Beretta, G., additional, Frontini, L., additional, Rulli, E., additional, and Sobrero, A., additional

Published
2017
Full Text
View/download PDF

33. Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial

Author

Di Bartolomeo, M., primary, Rosato, G., additional, Banzi, M., additional, Pella, N., additional, Zampino, M.G., additional, Rimassa, L., additional, Maiello, E., additional, Marchetti, P., additional, Lonardi, S., additional, Labianca, R., additional, Zaniboni, A., additional, Sobrero, A., additional, Ferrari, D., additional, Bidoli, P., additional, Iaffaioli, V., additional, De Placido, S., additional, Frassineti, L., additional, Frustaci, S., additional, Nicolini, M., additional, Vernieri, C., additional, and Galli, F., additional

Published
2017
Full Text
View/download PDF

34. The pre-emptive screening of multiple polymorphisms in gene-encoding dihydropyrimidine dehydrogenase (DPD) improve prevention of toxicity on patients candidate for fluoropyrimidine based-chemotherapy. An experience of the Reggio Emilia Cancer Center

Author

Iachetta, F., primary, Damato, A., additional, Bonelli, C., additional, Romagnani, A., additional, Banzi, M., additional, Nicoli, D., additional, Farnetti, E., additional, Casali, B., additional, and Pinto, C., additional

Published
2017
Full Text
View/download PDF

35. FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial

Author

Labianca, R., primary, Lonardi, S., additional, Rosati, G., additional, Di Bartolomeo, M., additional, Ronzoni, M., additional, Pella, N., additional, Scartozzi, M., additional, Banzi, M., additional, Zampino, M.G., additional, Pasini, F., additional, Marchetti, P., additional, Cantore, M., additional, Zaniboni, A., additional, Rimassa, L., additional, Ciuffreda, L., additional, Barni, S., additional, Zagonel, V., additional, Maiello, E., additional, Rulli, E., additional, and Sobrero, A., additional

Published
2017
Full Text
View/download PDF

36. 673PD - Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial

Author

Cascinu, S., Berardi, R., Bianco, R., Bilancia, D., Zaniboni, A., Ferrari, D., Mosconi, S., Spallanzani, A., Cavanna, L., Leo, S., Negri, F., Beretta, G.D., Sobrero, A., Banzi, M., Morabito, A., Bittoni, A., Marciano, R., Ferrara, D., Noventa, S., and Piccirillo, M.C.

Published
2019
Full Text
View/download PDF

37. 553P - Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group

Author

De Gramont, A., Henriques, J., Baruch, B., Kim, T.W., Martinez-Villacampa, M., Gallego-Plazas, J., Cervantes, A., Shim, K., Jonker, D.J., Guerin-Meyer, V., Mineur, L., Banzi, M., Dewdney, A., Dejthevaporn, T Sirisingha, Bloemendal, H.J., Roth, A.D., Thompson, P., Moehler, M., Aguilar, E Aranda, and André, T.

Published
2019
Full Text
View/download PDF

39. Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial

Author

Lonardi, S., primary, Sobrero, A., additional, Rosati, G., additional, Di Bartolomeo, M., additional, Ronzoni, M., additional, Aprile, G., additional, Scartozzi, M., additional, Banzi, M., additional, Zampino, M.G., additional, Pasini, F., additional, Marchetti, P., additional, Cantore, M., additional, Zaniboni, A., additional, Rimassa, L., additional, Ciuffreda, L., additional, Ferrari, D., additional, Barni, S., additional, Zagonel, V., additional, Maiello, E., additional, Rulli, E., additional, Labianca, R., additional, Bilancia, D., additional, Montesarchio, V., additional, Iaffaioli, R.V., additional, Nasti, G., additional, Daniele, B., additional, Lonardi, S., additional, Pella, N., additional, Romiti, A., additional, Foa, P., additional, Mosconi, S., additional, Bidoli, P., additional, Cazzaniga, M., additional, Beretta, G.D., additional, Corsi, D.C., additional, Cortesi, E., additional, Petrelli, F., additional, Cinieri, S., additional, Santoro, A., additional, Artioli, F., additional, Mattioli, R., additional, Amoroso, D., additional, Amadori, D., additional, Frassineti, L., additional, Turci, D., additional, Ravaioli, A., additional, Bajetta, E., additional, Gianni, L., additional, Ionta, M.T., additional, Massidda, B., additional, Bochicchio, A., additional, Ciarlo, A., additional, Di Leo, A., additional, De Placido, S., additional, Carlomagno, C., additional, Adamo, V., additional, Natale, D., additional, Galli, F., additional, Poli, D., additional, and Torri, V., additional

Published
2016
Full Text
View/download PDF

44. P-237 - Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial

Author

Dell'Aquila, E., Pantano, F., Rossini, D., Stellato, M., Lonardi, S., Masi, G., Schirripa, M., Marmorino, F., Antoniotti, C., Murgioni, S., Tomasello, G., Ronzoni, M., Racca, P., Vincenzi, B., Allegrini, G., Urbano, F., Buonadonna, A., Banzi, M., Tonini, G., Cremolini, C., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

45. Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III 'BEBYP'trial by the Gruppo Oncologico Nord Ovest (GONO)

Author

GIANLUCA MASI, Loupakis, F., Salvatore, L., CHIARA CREMOLINI, Fornaro, L., Schirripa, M., Granetto, C., Miraglio, E., Di Costanzo, F., Antonuzzo, L., Marcucci, L., Barbara, C., Boni, C., Banzi, M., Chiara, S., Garbarino, D., Valsuani, C., Bonetti, A., Boni, L., and Alfredo Falcone

Published
2013

46. A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO)

Author

Salvatore, L., GIANLUCA MASI, Loupakis, F., CHIARA CREMOLINI, Schirripa, M., Fornaro, L., Antoniotti, C., Vivaldi, C., Granetto, C., Fea, E., Antonuzzo, L., Giommoni, E., Boni, C., Banzi, M., Chiara, S., Sonaglio, C., Allegrini, G., Marcucci, L., Valsuani, C., Greco, F., Safina, V., Boni, L., and Alfredo Falcone

Published
2012

47. Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status

Author

Sobrero, A., primary, Latini, L., additional, Barone, C., additional, Capuzzo, F., additional, Banzi, M., additional, Nasroulah, F., additional, Sims, L., additional, and Tabernero, J., additional

Published
2015
Full Text
View/download PDF

48. Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study

Author

Ciardiello, F., primary, Salvatore, L., additional, Cascinu, S., additional, Sobrero, A., additional, Banzi, M., additional, Barone, C., additional, Spallanzani, A., additional, Latiano, T.L., additional, Amatu, A., additional, Zagonel, V., additional, Biglietto, M., additional, Di Costanzo, F., additional, Di Bartolomeo, M., additional, Santoro, A., additional, Russo, A., additional, Moscovici, M., additional, Van Cutsem, E., additional, and Zaniboni, A., additional

Published
2015
Full Text
View/download PDF

49. CTC subpopulations in metastatic breast cancer

Author

Bulfoni, M., primary, Gerratana, L., additional, Puglisi, F., additional, Beltrami, A.P., additional, Di Loreto, C., additional, Bonotto, M., additional, Cinausero, M., additional, Bozza, C., additional, Isola, M., additional, Toffoletto, B., additional, Marzinotto, S., additional, Minisini, A.M., additional, Sottile, R., additional, Banzi, M., additional, Peruzzi, E., additional, Mansutti, M., additional, Fasola, G., additional, and Cesselli, D., additional

Published
2015
Full Text
View/download PDF

50. 1890 Look up the meaning of distinct circulating tumor cells in metastatic breast cancer

Author

Gerratana, L., primary, Bulfoni, M., additional, Beltrami, A.P., additional, Di Loreto, C., additional, Bonotto, M., additional, Cinausero, M., additional, Isola, M., additional, Toffoletto, B., additional, Marzinotto, S., additional, Minisini, A.M., additional, Sottile, R., additional, Banzi, M., additional, Peruzzi, E., additional, Mansutti, M., additional, Fasola, G., additional, Puglisi, F., additional, and Cesselli, D., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results